» Articles » PMID: 34071504

Horizontal Transfer of MiR-643 from Cisplatin-Resistant Cells Confers Chemoresistance to Recipient Drug-Sensitive Cells by Targeting APOL6

Overview
Journal Cells
Publisher MDPI
Date 2021 Jun 2
PMID 34071504
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Acquisition of resistance to cisplatin is a major impediment to the success of cisplatin-based combination therapies for cancer. Recent studies indicate that exosomal miRNAs derived from drug-resistant tumour cells can confer resistance properties to recipient cells by a horizontal transfer mechanism. Although the role of horizontal transfer of a few miRNAs has been described, little is known about the concerted action of horizontal transfer of miRNAs in conferring cisplatin resistance. The present study was designed to identify the role of miR-643, which is one of the most significantly increased miRNA in exosomes released from cisplatin-resistant Heptocarcinoma cells, in altering the cisplatin resistance properties of recipient cells. Drug-sensitivity assays involving miR-643 revealed that ectopic expression of miR-643 can desensitise the cells towards cisplatin. Furthermore, we identified APOL6 as a major target of miR-643. Further mechanistic studies showed that miR-643 can modulate APOL6 mRNA and protein levels, leading to a reversal of APOL6-mediated apoptosis. Altogether, our results suggest an APOL6-dependent mechanism for miR-643 mediated cisplatin resistance upon the horizontal transfer across cell types.

Citing Articles

Extracellular Vesicles as Mediators and Potential Targets in Combating Cancer Drug Resistance.

Zhang H, Wu B, Wang Y, Du H, Fang L Molecules. 2025; 30(3).

PMID: 39942602 PMC: 11819960. DOI: 10.3390/molecules30030498.


Unveiling retrotransposon-derived DNA zip code for myeloma cell internalization.

Puvvula P, Johnson A, Bernal-Mizrachi L Oncoscience. 2024; 11:58-64.

PMID: 39015604 PMC: 11251427. DOI: 10.18632/oncoscience.606.


Horizontal transfer of miR-383 sensitise cells to cisplatin by targeting VEGFA-Akt signalling loop.

Raji G, Poyyakkara A, Sruthi T, Edatt L, Haritha K, Shankar S Mol Biol Rep. 2024; 51(1):286.

PMID: 38329638 DOI: 10.1007/s11033-023-09195-6.


Research on radiotherapy related genes and prognostic target identification of rectal cancer based on multi-omics.

Liu Y, Yang Y, Ni F, Tai G, Yu C, Jiang X J Transl Med. 2023; 21(1):856.

PMID: 38012642 PMC: 10680259. DOI: 10.1186/s12967-023-04753-9.


Exosomes in Cancer Progression and Therapy Resistance: Molecular Insights and Therapeutic Opportunities.

Wandrey M, Jablonska J, Stauber R, Gul D Life (Basel). 2023; 13(10).

PMID: 37895415 PMC: 10608050. DOI: 10.3390/life13102033.


References
1.
Ishida S, Lee J, Thiele D, Herskowitz I . Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A. 2002; 99(22):14298-302. PMC: 137878. DOI: 10.1073/pnas.162491399. View

2.
Cimmino A, Calin G, Fabbri M, Iorio M, Ferracin M, Shimizu M . miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005; 102(39):13944-9. PMC: 1236577. DOI: 10.1073/pnas.0506654102. View

3.
Wang H, Xing D, Ren D, Feng W, Chen Y, Zhao Z . MicroRNA‑643 regulates the expression of ZEB1 and inhibits tumorigenesis in osteosarcoma. Mol Med Rep. 2017; 16(4):5157-5164. PMC: 5647050. DOI: 10.3892/mmr.2017.7273. View

4.
Zhao L, Liu W, Xiao J, Cao B . The role of exosomes and "exosomal shuttle microRNA" in tumorigenesis and drug resistance. Cancer Lett. 2014; 356(2 Pt B):339-46. DOI: 10.1016/j.canlet.2014.10.027. View

5.
Ambros V . microRNAs: tiny regulators with great potential. Cell. 2002; 107(7):823-6. DOI: 10.1016/s0092-8674(01)00616-x. View